Citigroup
SGTX

Citigroup’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Citigroup’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-35
Closed – – 6547
2022
Q2 		$0 Sell
35
-59
-63% -$793 ﹤0.01% 6834
2022
Q1 		$2K Sell
94
-205
-69% -$4.57K ﹤0.01% 6120
2021
Q4 		$11K Buy
299
+166
+125% +$9.45K ﹤0.01% 5550
2021
Q3 		$10K Buy
133
+106
+393% +$8.16K ﹤0.01% 5479
2021
Q2 		$4K Sell
27
-12
-31% -$2.11K ﹤0.01% 5892
2021
Q1 		$11K Sell
39
-694
-95% -$276K ﹤0.01% 5610
2020
Q4 		$457K Buy
+733
New +$333K ﹤0.01% 4286

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citigroup's SGTX Position: Q3 2022 in Review

Citigroup sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2022, closing a stake of 35 shares.

Citigroup first reported a position in SGTX in Q4 2020 and held it in 7 quarters. The position peaked at $457K in Q4 2020. 33 funds tracked by Wall St. Rank hold SGTX as of Q3 2022.

  • Citigroup reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 35 Sigilon Therapeutics, Inc. Common Stock shares in Q3 2022.
  • Citigroup first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
  • Citigroup's Sigilon Therapeutics, Inc. Common Stock position peaked at $457K in Q4 2020.
  • 33 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.